|Articles|September 20, 2021
Seasonal Vaccine Manufacturing v2
Author(s)Baxter BioPharma Solutions
The seasonal influenza vaccine market is projected to reach more than $4 Billion USD by the end of 2022. It is a safe assumption that as demand for seasonal influenza vaccines increases, so too with the demand for contract manufacturing organizations (CMOs) to support.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5